A 60-year-old, chronic smoker presented with gradual and slowly progressive shoness of breath for 5 months along with dry cough along with malaise and fatigue. There was no history of haemoptysis, chest pain or occupational exposure. Chest x-ray, HRCT chest were done. Lung Biopsy was planned. Which of the following drug has been recently approved for the above condition: –

## **Core Concept**
The patient's symptoms of gradual shortness of breath, dry cough, malaise, and fatigue, combined with a history of chronic smoking, suggest a diagnosis of **Idiopathic Pulmonary Fibrosis (IPF)**. IPF is a chronic, progressive lung disease characterized by fibrosis of the lung tissue, leading to impaired lung function. The diagnosis is often confirmed through imaging studies like HRCT and lung biopsy.

## **Why the Correct Answer is Right**
The correct answer, **Nintedanib**, is a **tyrosine kinase inhibitor** that has been specifically approved for the treatment of IPF. It works by blocking the activity of certain tyrosine kinases, including VEGFR, FGFR, and PDGFR, which are involved in the fibrotic process. By inhibiting these kinases, nintedanib reduces the progression of fibrosis in the lung. This mechanism of action makes it an effective treatment option for IPF.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Pirfenidone is indeed used for IPF but works as an anti-fibrotic and anti-inflammatory agent. It is not the correct answer based on the question's specifics about recent approval and mechanism.
- **Option B:** Azathioprine is an immunosuppressive drug used in various conditions but is not specifically approved for IPF and has a different mechanism of action.
- **Option D:** Acetylcysteine is used as a mucolytic agent and has antioxidant properties but is not specifically approved for the treatment of IPF.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **Nintedanib and Pirfenidone** are the two drugs that have been specifically approved for the treatment of **Idiopathic Pulmonary Fibrosis (IPF)**. Nintedanib's recent approval and unique mechanism of action as a tyrosine kinase inhibitor make it a significant treatment option.

## **Correct Answer:** .

✓ Correct Answer: A. Nintedanib